Skip to main content
Home

Breadcrumb

  1. Home
  2. Healthcare and Life Science

Healthcare and Life Science

Analytics for clinical development strategy: Integrated optimization of an oncology program
15 November 2024

Analytics for clinical development strategy: Integrated optimization of an oncology program

Achieving a return on invested capital (ROIC) that exceeds the cost of capital remains a challenge for pharmaceutical R&D. To make progress, there needs to be consistent and rigorous modeling of the clinical and commercial determinants of ROIC. In the second of three articles, CRA’...

CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?
15 November 2024

CMS’ Alzheimer’s NCD: Outlier or harbinger of increased scrutiny?

Aduhelm was the first FDA-approved disease-modifying treatment for Alzheimer’s, sparking debate among providers, regulators, and patients. Aduhelm received a controversial accelerated approval from the FDA in June 2021, a decision that balanced the lack of consensuses among the scientif...

Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D
5 November 2024

Analytics for clinical development strategy: A unified approach to optimizing return on investment in R&D

Despite the rapid scientific advances with new targets, modalities, and biomarkers, the return on invested capital (ROIC) in novel therapeutics remains low. The problem stems from the large investment needed, high risks of failure, and long timelines until revenues can be realized. This...

Infertility - A public health concern
4 November 2024

Infertility - A public health concern

The World Health Organization (WHO) estimates that one out of six people globally are impacted by the inability to conceive a child. Over the last decade, countries around the world have seen a decline in total fertility rates, most notably in economically developed countries withi...

Winners of the OBN Awards 2024
21 November 2024

Shining a light on the life sciences

The OBN Awards struck an optimistic tone as the best of the UK’s life sciences industry was celebrated Abingdon, UK, 21 November 2024: – OBN (UK) Ltd is thrilled to announce the winners of the prestigious OBN Awards 2024. This was the 16th year of the Awards, which OBN (UK) Ltd, the no...

logo
22 November 2024

Medicilon delivers fast turnaround time to meet your FDA submission deadline for SEND Format Conversion

Medicilon's preclinical pharmacology and toxicology research team is equipped with a professional send format conversion team and has established a send data conversion platform that is fully developed in terms of software, technology, specification and quality, to realize accurate data...

Glox Therapeutics supported by PACE
20 November 2024

Glox Therapeutics awarded £1M PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant pathogens

Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects Glasgow, UK, 20 November...

COPD
20 November 2024

COPD management: a critical look at gaps in pharmaceutical innovation

Chronic Obstructive Pulmonary Disease (COPD) presents a major global health challenge, marked by chronic respiratory decline and frequent exacerbations. Despite advances in treatment, comprehensive management strategies remain limited, revealing significant gaps in patient care. ...

Spheroid confocal spinning disk (left) and holotomography acquisitions (right).
20 November 2024

CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform

First commercially available spinning-disk confocal holotomographic instrument, enabling advanced 3D imaging with fluorescence-based detection New system showcased at SPAOM24 (20th-22nd November, Toledo, Spain) Rome, IT, 20 November, 2024: CrestOptics S.p.A., a manufacturer of high...

The Tagomics team
20 November 2024

Tagomics announces a multiomic profiling co-marketing agreement with Agilent

Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis ...

Pagination

  • First page «
  • Previous page ‹‹
  • …
  • Page 108
  • Page 109
  • Current page 110
  • Page 111
  • Page 112
  • …
  • Next page ››
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS